Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 17/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17076642 | 1.00 | AAK1 (0.51) | AAK1GAAMAPTSMN1; SMN2KRAS | |
| SCHEMBL21455348 | 1.00 | AAK1 (0.51) | AAK1GAAMAPTSMN1; SMN2KRAS | |
| SCHEMBL24629450 | 0.90 | GAA (0.42) | AAK1GAAMAPTSMN1; SMN2KDM4E | |
| SCHEMBL29769194 | 0.90 | GAA (0.42) | AAK1GAAMAPTSMN1; SMN2KDM4E | |
| SCHEMBL21455142 | 0.90 | AAK1 (0.45) | AAK1GAAMAPTSMN1; SMN2KRAS | |
| SCHEMBL16440168 | 0.82 | AAK1 (0.43) | AAK1KRASSOS1 | |
| SCHEMBL13681594 | 0.81 | CHRNB4 (0.46) | AAK1GAAMAPTSMN1; SMN2KDM4E | |
| SCHEMBL2789738 | 0.81 | CHRNB4 (0.46) | AAK1GAAMAPTSMN1; SMN2KDM4E | |
| SCHEMBL5122248 | 0.81 | CHRNB4 (0.46) | AAK1GAAMAPTSMN1; SMN2KDM4E | |
| SCHEMBL31392972 | 0.80 | MAPT (0.41) | AAK1GAAMAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3553064-B1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-20220153766-A1 | CONDENSED TRICYCLIC COMPOUND USED AS KINASE INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-10968234-B2 | Compound containing tricyclic heteroaryl group | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-10934311-B2 | Heterocyclic compound used as FGFR inhibitor | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20200354376-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| WO-2020188467-A1 | CONDENSED TRICYCLIC COMPOUND USED AS KINASE INHIBITOR | 杭州英创医药科技有限公司 | 2020-09-24 | — | — | WO | disclosed |
| US-10730887-B2 | Compound containing tricyclic heteroaryl group | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-08-04 | — | — | US | disclosed |
| EP-3553064-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2019-10-16 | — | — | EP | disclosed |
| US-20190308993-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-10-10 | — | — | US | disclosed |
| US-20190100531-A1 | HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153766-A1 | CONDENSED TRICYCLIC COMPOUND USED AS KINASE INHIBITOR | HCK, SBK1, ALK | AAK1 72/4885GAA 3239/4885MAPT 2115/4885 |
| US-20190308993-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | JAK3, ERBB3, CDK3 | AAK1 732/4885GAA 3047/4885MAPT 2915/4885 |
| US-20190100531-A1 | HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | AAK1 1472/4885GAA 1045/4885MAPT 1756/4885 |
| US-10934311-B2 | Heterocyclic compound used as FGFR inhibitor | FGFR1, FGFR3, FGFR2 | AAK1 1472/4885GAA 1045/4885MAPT 1756/4885 |
| US-10968234-B2 | Compound containing tricyclic heteroaryl group | JAK3, ERBB3, CDK3 | AAK1 713/4885GAA 3217/4885MAPT 3013/4885 |
| US-20200354376-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | JAK3, ERBB3, CDK3 | AAK1 713/4885GAA 3217/4885MAPT 3013/4885 |
| US-10730887-B2 | Compound containing tricyclic heteroaryl group | JAK3, ERBB3, CDK3 | AAK1 732/4885GAA 3047/4885MAPT 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.